Next Article in Journal
Telemedicine Applications in Pediatric Retinal Disease
Next Article in Special Issue
Factor VII Deficiency: Clinical Phenotype, Genotype and Therapy
Previous Article in Journal / Special Issue
Italian Registry of Congenital Bleeding Disorders
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessFeature PaperReview
J. Clin. Med. 2017, 6(3), 35; doi:10.3390/jcm6030035

The History of Clotting Factor Concentrates Pharmacokinetics

Past President of Italian Association of Haemophilia Centres (AICE), Via dello Statuto n.1, I-50129 Firenze, Italy
Academic Editor: Emmanuel Andrès
Received: 29 January 2017 / Revised: 3 February 2017 / Accepted: 7 March 2017 / Published: 20 March 2017
(This article belongs to the Special Issue Outstanding Advances in Hemophilia Therapies)
View Full-Text   |   Download PDF [253 KB, uploaded 20 March 2017]

Abstract

Clotting factor concentrates (CFCs) underwent tremendous modifications during the last forty years. Plasma-derived concentrates made the replacement therapy feasible not only in the hospital but also at patients’ home by on-demand or prophylactic regimen. Virucidal methods, implemented soon after hepatitis and AIDS outbreak, and purification by Mabs made the plasma-derived concentrates safer and purer. CFCs were considered equivalent to the other drugs and general rules and methods of pharmacokinetics (PK) were applied to their study. After the first attempts by graphical methods and calculation of In Vivo Recovery, compartment and non-compartment methods were applied also to the study of PK of CFCs. The bioequivalence of the new concentrates produced by means of recombinant DNA biotechnology was evaluated in head-to-head PK studies. Since the beginning, the large inter-patient variability of dose/response of replacement therapy was realized. PK allowed tailoring haemophilia therapy and PK driven prophylaxis resulted more cost effective. Unfortunately, the need of several blood samples and logistic difficulties made the PK studies very demanding. Recently, population PK (PopPK) has been applied to the prediction of CFCs dosing by Bayesian methodology. By PopPK also sparse data may allow evaluating the appropriateness of replacement therapy. View Full-Text
Keywords: clotting factor concentrates; pharmacokinetics; compartment methods; Non-Compartment Analysis; Bayesian compromise; PopPK; prophylaxis; In Vivo Recovery; Clearance; Half-life; Volume of distribution clotting factor concentrates; pharmacokinetics; compartment methods; Non-Compartment Analysis; Bayesian compromise; PopPK; prophylaxis; In Vivo Recovery; Clearance; Half-life; Volume of distribution
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Morfini, M. The History of Clotting Factor Concentrates Pharmacokinetics. J. Clin. Med. 2017, 6, 35.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top